Extensively Hydrolyzed Formula Growth Monitioring Study (GMS) (NCT07513506) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Extensively Hydrolyzed Formula Growth Monitioring Study (GMS)
United States214 participantsStarted 2026-04-03
Plain-language summary
This is a research study to compare an investigational infant formula against a currently marketed infant formula. An investigational infant formula is one that has never been approved by the United States Food and Drug Administration (FDA).
The purpose of this research study is to evaluate the growth and tolerance of infants who consume a new (not yet available to buy) extensively hydrolyzed cow milk protein infant formula compared to an extensively hydrolyzed cow milk protein infant formula that is currently available to buy. The study will also look at the growth of your baby, how many poops your baby has, what the poops are like (for example, soft or hard), how much study formula your baby drinks, how well your baby handles the study formula (such as spit-up, fussiness, gas, colic, or changes in sleep), and any health problems that might come up during the study.
Who can participate
Age range10 Days – 14 Days
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 10 to 14 days of age at randomization, inclusive (day of birth is considered Day 0)
* Singleton birth
* Gestational age of 37 weeks + 0 days to 41 weeks + 6 days, inclusive
* Birth weight of 2500 g to 4200 g, inclusive
* Birth weight appropriate for gestational age (AGA, defined as birth weight-for-age between 10th and 90th percentile, inclusive)
* Exclusively receiving infant formula for at least 24 hours prior to randomization
* Parent(s) or legal guardian(s) have full intention to exclusively feed their infant study formula through 126 days of age
* Signed informed consent obtained from parent or legal guardian for infant's participation in the study
* Signed authorization obtained from parent or legal guardian to use and/or disclose Protected Health Information for the infant from birth through the length of the study period
* Parent or legal guardian agrees not to enroll the infant in another interventional clinical study while participating in this study
* Decentralized participant's parent/caregiver or legal guardian has access to reliable internet and technology for remote visits.
* Decentralized participant's parent/caregiver or legal guardian anticipates having a second adult available for all remote visits.
Exclusion Criteria:
* History of underlying metabolic or chronic disease; congenital malformation; immunodeficiency, gastrointestinal condition, or any other condition which, in the opinion of the Investigator, is likely to interfere wit…